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ABSTRACT
Malignant pleural mesothelioma (MPM), a fatal cancer, is an occupational disease 
mostly affecting workers ex-exposed to asbestos fibers. The asbestos, a cancerogenic 
mineral of different chemical composition, was widely employed in western Countries 
in industrial manufactures of different types. MPM may arise after a long latency 
period, up to five decades. MPM is resistant to conventional chemo- and radio-
therapies. Altogether, these data indicate that the identification of new and specific 
markers are of a paramount importance for an early diagnosis and treatment of MPM. 
In recent years, microRNAs expression was found dysregulated in patients, both 
in cancer cells and sera, affected by tumors of different histotypes, including MPM. 
Cell and circulanting microRNAs, found to be dysregulated in this neoplasia, were 
proposed as new biomarkers. It has been reported that circulating microRNAs are 
stable in biological fluids and could be employed as potential MPM biomarkers. In 
this investigation, circulating microRNAs (miR) from serum samples of MPM patients 
and workers ex-exposed to asbestos fibers (WEA) and healthy subjects (HS) were 
comparatively analyzed by microarray and RT-qPCR technologies. Our results allowed 
(i) to select MiR-3665, an endogenous stable microRNA, as the internal control to 
quantify in our analyses circulating miRNAs; to detect (ii) miR-197-3p, miR-1281 and 
miR 32-3p up-regulated in MPM compared to HS; (iii) miR-197-3p and miR-32-3p up-
regulated in MPM compared to WEA; (iv) miR-1281 up-regulated in both MPM and WEA 
compared to HS. In conclusion, three circulating up-regulated microRNAs, i.e. miR-
197-3p, miR-1281 and miR-32-3p are proposed as potential new MPM biomarkers.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is a fatal 
cancer, with an increasing incidence worldwide. MPM, 
which is resistant to conventional chemo- and radio-
therapies, is often diagnosed in a late stage with a median 
survival of 12 months. Exposure to asbestos fibers is the 
main risk factor for the MPM onset [1], which may occur 
in workers even decades after exposure to this tumorigenic 
mineral. Recent data indicate that asbestos is becoming an 
environmental pollutant, with the consequence that MPM 
patients not always are linked to the occupational disease 
[2]. Asbestos, after been recognized as a carcinogenic 
agent [3], was banned in different European Countries 
at various time-points between 1970-2005 [4, 5]. It was 
estimated that about 250,000 people will die of this tumour 
in Europe in the coming decades [6, 7].
Considering the long latency period of MPM 
onset, subjects potentially at risk may benefit of an 
early diagnosis based on specific biomarkers [8]. Many 
studies attempted to identify specific biomarkers that 
may predict the evolution of this malignancy without 
firm conclusions [9–12]. Indeed, the identification of 
new and specific markers is of a paramount importance 
for an early detection, diagnosis, and treatment of MPM, 
together with the evolution of this malignancy [13]. In 
recent years, together with protein markers, microRNAs 
(miRNAs) from MPM cells or sera, have been proposed as 
new biomarkers [14–16]. MiRNAs, a family of small non-
coding RNAs, approximately 21-25 nt long, negatively 
regulate the gene expression by inhibiting translation of 
target messenger RNAs (mRNAs) through pairing with 
mRNA recognition elements (MREs), usually in 3′-UTRs 
[17]. Circulating miRNAs are packaged in microparticles, 
such as exosomes, microvesicles and apoptotic bodies or 
by their association with RNA binding protein including 
Argonaute 2 (Ago2) or lipoprotein complexes like the 
high-density lipoprotein (HDL), with the final effect of 
enhancing their stability in biological fluids [18]. It was 
hypothesized that these miRNAs detectable in serum 
samples, may allow to study the inter-cellular information 
flow [19–21].
Dysregulated miRNAs have been detected in 
several cancers of different histotypes [22]. Many 
investigations indicate that miRNAs may be used as 
diagnostic biomarkers for cancers, including MPM [23, 
24] and potential new targets for innovative therapeutic 
approaches [25].
In a previous study we identified a group of 
22 miRNAs significantly dysregulated in MPM cells 
compared to normal mesothelial cells. Some of these 
miRNAs belong to miR-17-92 cluster, which is induced 
by c-Myc oncogene [14].
Herein, we report on the comparative analysis of 
miRNA expression in serum samples from MPM affected 
patients and workers ex-exposed to asbestos fibers (WEA) 
and healthy subjects (HS). The aim of this investigation 
was to identify extracellular miRNAs as (i) putative 
biomarkers for MPM; (ii) predictive markers of MPM in 
WEA; (iii) potential targets for innovative therapies.
RESULTS
Microarray analysis
In our investigation, circulating miRNAs from 
serum samples of MPM patients (n=10) and workers 
(n=10), both groups belonging to ex-exposed asbestos 
fibers, and healthy subjects (n=10), were analysed by 
microarray (Agilent Technologies, Human miRNA 
microarray G4470A) and RT-qPCR technologies.
Among the 1,201 miRNAs assessed with microarray 
technology, 197 miRNAs were identified to be detected 
in at least 1 out of 30 samples analyzed. It is worth 
noting that the total number of circulating microRNAs 
in the three cohorts was different. Indeed, differences 
in miRNA expression profiles of MPM, WEA and HS 
were identified, with more miRNAs detected in serum 
of healthy subjects compared to that of MPM and WEA. 
Specifically, 145 miRNAs out of 1,201 were detected in 
healthy subjects, whereas they were 119 in MPM and 42 
in WEA. The difference between: HS and MPM, i.e 145 
vs 119, p=0.053; HS vs WEA, i.e. 145 vs 42, p<0.0001; 
MPM vs WEA, i.e. 119 vs 42, p<0.0001, are statistically 
significant (Figure 1).
Among the 119 miRNAs expressed in MPM, 67 
miRNAs were also detected in the control sample of 
HS. The remaining 52 miRNAs were expressed only in 
the MPM samples. In the WEA cohort 42 miRNAs were 
expressed, but none was expressed exclusively in this 
cohort. A total of 145 miRNAs were expressed in HS, i.e. 
76 miRNAs were detected in this cohort only, whereas 
27 were in common with MPM, 2 were in common with 
WEA and 40 were expressed in all the three groups of 
patients/subjects studied (Figure 2).
Dysregulated miRNA expression was detected in 
serum samples from MPM patients, compared to WEA 
and HS. Comparing with ANOVA test the miRNAs 
expression in the three groups (MPM, WEA and HS) 
37 miRNAs were found to be significantly dysregulated 
(Figure 3 and Table 1).
Validation by RT-qPCR of stable circulating 
miRNAs
The normalization of data is a prerequisite to 
verify whether false negative/positive results may 
occur. In addition, this normalization is necessary to 
reduce some of the potential technical variations, such 
as the kind of sample, the method of RNA extraction, 
miRNA quantification methods. To this purpose in 
our experiments, endogenous stable miRNAs were 
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Figure 1: Total number of miRNAs detected in the three cohorts MPM, WEA and HS analyzed by microarray 
technology. The difference between: HS and MPM, i.e 145 vs 119, p=0.053; HS vs WEA, i.e. 145 vs 42, p<0.0001; MPM vs WEA, i.e. 
119 vs 42, p<0.0001, are statistically significant.
Figure 2: Venn diagram showing miRNAs detected in sera from the three MPM, WEA, HS cohorts analyzed. MiRNAs 
(n=119) expressed in MPM are in blue, n=42 are those detected in WEA cohort, in gree, whereas n=145 are the miRNAs detected in HS, 
in red. MiRNAs n=52 are expressed in MPM samples only. N=76 are expressed in the HS only. None of the MiRNAs (n=42) detected in 
the WEA cohort was unique of this cohort. Indeed, n=40 were in common with MPM and HS, n=2 were in common with HS only. N=27 
miRNAs were found in common between MPM and HS.
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investigated. Herein, microarray results indicated three 
endogenous unvariable expressed miRNAs, i.e. miR-
1234-3p, miR-3656 and miR-3665. Specifically, these 
three candidate control miRNAs were selected because 
showing the less expression variability in microarray 
analysis across all analyzed sera.
Then, RT-qPCR technique was employed to validate 
the data on the three stable miRNAs obtained with the 
microarray approach. These RT-qPCR analyses were 
carried out in the 30 sera (n=10 MPM, n=10 WEA and 
n=10 HS), analyzed before by microarray technology, 
together with additional 19 serum samples from MPM, 
n=10; WEA, n=5; HS, n=4, for a total of 49 sera.
In order to verify whether the three candidate 
stable miRNAs could be used as controls, the average 
coefficient of variation (CV), across the three different 
cohorts, was evaluated. ANOVA test was employed to 
study the differences in mean ΔCT of the three candidate 
stable miRNAs in the three MPM, WEA and HS groups. 
Moreover, the NormFinder software was used to verify 
the S parameter, which is the relative value indicating the 
stable miRNA expression. Three values, i.e. CV, ANOVA 
and S parameter, were employed to select the more stable 
microRNA among the 49 samples analyzed. CV values 
resulted, 0.035%, 0.023% and 0.023% for miR-1234-3p, 
miR-3656 and miR-3665, respectively. For miR-1234-3p 
ANOVA test showed p = 0.81, for miR-3656 resulted p 
= 0.57 and p = 0.81 for miR-3665. S parameter resulted, 
0.024, 0.027, 0.021 for miR-1234-3p, miR-3656 and miR-
3665, respectively. Statistical analyses of microarray and 
RT-qPCR data showed no different expression for these 
three miRNA among the three cohorts. Although RT-qPCR 
confirmed the stable expression for the three candidate 
stable miRNAs, miR-3665 demonstrated the minimum 
CV, the maximum ANOVA value and the minimum S 
value, as expected for a significant data. Therefore, miR-
3665 demonstrated the higher stable expression in our 
samples. This result led us to select miR-3665 as stable 
endogenous control for circulating miRNAs quantification 
in our cohorts. Moreover, this miRNA was selected as 
housekeeping to perform the relative quantification of 
miRNAs differentially expressed by the use of the value 
of fold changes (FC) calculated using the equation:
2-Δ(ΔCt), where ΔΔCt=(CtmiR-CtHKmiR-3665)MMP-(CtmiR-
CtHKmiR-3665)HS.
Figure 3: Cluster analysis of microRNA expression profiles in sera from MPM, WEA and HS cohorts.
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It is worth noting that until now, no HK standard 
for the circulating miRNA studies was identified 
in different studies carried out in this field. In our 
investigation an internal miRNA control, miR-3665, 
was selected. Indeed, this endogenous housekeeping 
gene showed consistently the same expression level in 
normal and patient samples.
Table 1: MiRNAs detected dysregulated in three groups by microarray analysis
n Systematic name
Normalized data MPM vs HS MPM vs WEA WEA vs HS False 
discovery rateMPM WEA HS Regulation FC Regulation FC Regulation FC
1 let-7b-5p −1,1021 −3,2156 −2,4594 up 2,5620 up 4,3271 down −1,6890 5,25
2 miR-1180 −0,6633 −3,2156 −2,2398 up 2,9824 up 5,8656 down −1,9667 5,08
3 miR-1202 1,2882 4,1715 2,5602 down −2,4151 down −7,3785 up 3,0552 8,17
4 miR-1228-5p 0,3912 −3,2156 −2,0449 up 5,4117 up 12,1823 down −2,2511 0,70
5 miR-1249 −3,0104 −3,2156 −1,7707 down −2,3615 up 1,1528 down −2,7223 1,90
6 miR-1281 3,4131 3,2472 1,5335 up 3,6796 up 1,1218 up 3,2800 9,80
7 miR-1306-3p −0,6182 −3,2156 −2,0092 up 2,6226 up 6,0519 down −2,3076 7,16
8 miR-150-3p −3,2695 −3,2156 −2,2309 down −2,0542 down −1,0381 down −1,9788 5,16
9 miR-188-5p −3,0793 −3,2156 −1,8494 down −2,3454 up 1,0991 down −2,5778 1,90
10 miR-197-3p −0,7610 −3,2156 −2,9142 up 4,4480 up 5,4815 down −1,2323 4,75
11 miR-2276 −3,2695 −3,2156 −2,0743 down −2,2898 down −1,0381 down −2,2058 4,75
12 miR-2278 0,7015 −2,9345 −1,9823 up 6,4258 up 12,4323 down −1,9347 0,22
13 miR-3148 1,8715 −3,2156 −1,8038 up 12,7759 up 33,9906 down −2,6605 0,01
14 miR-3149 3,3830 −2,8135 −0,9095 up 19,5963 up 73,3389 down −3,7425 0,01
15 miR-3188 −3,2695 −3,2156 −2,3036 down −1,9532 down −1,0381 down −1,8815 8,37
16 miR-3196 −2,1135 0,9510 1,5813 down −12,9485 down −8,3654 down −1,5479 8,17
17 miR-32-3p 3,1347 −2,8072 −1,0024 up 17,5959 up 61,4774 down −3,4939 0,01
18 miR-3202 −3,2695 −3,2156 −1,9073 down −2,5708 down −1,0381 down −2,4765 1,43
19 miR-320e −3,2695 −3,2156 −2,4206 down −1,8011 down −1,0381 down −1,7351 1,52
20 miR-324-3p −2,1411 −3,2156 −3,0620 up 1,8933 up 2,1059 down −1,1123 7,31
21 miR-3610 −3,2695 −3,2156 −2,4331 down −1,7856 down −1,0381 down −1,7201 8,37
22 miR-3676-3p −0,9013 1,8540 −0,0857 down −1,7600 down −6,7518 up 3,8363 4,75
23 miR-3679-5p −1,3530 −2,8888 0,2802 down −3,1020 up 2,8996 down −8,9947 4,75
24 miR-3907 −2,2813 −3,2156 −3,1256 up 1,7953 up 1,9109 down −1,0644 7,44
25 miR-3911 −3,2695 −3,2156 −2,2902 down −1,9715 down −1,0381 down −1,8991 4,69
26 miR-3937 −3,2695 −3,2156 −2,3920 down −1,8371 down −1,0381 down −1,7697 4,75
27 miR-4271 −3,0353 −3,2156 −2,0329 down −2,0033 up 1,1331 down −2,2699 4,75
28 miR-4306 −3,2695 −3,2156 −2,4794 down −1,7291 down −1,0381 down −1,6657 7,51
29 miR-4327 −3,2695 −3,2156 −2,2034 down −2,0936 down −1,0381 down −2,0169 9,69
30 miR-514b-5p −3,2695 −3,2156 −2,5183 down −1,6831 down −1,0381 down −1,6214 1,10
31 miR-548am-5p −2,0017 −3,2156 −3,2610 up 2,3938 up 2,3196 up 1,0320 5,08
32 miR-548q −3,2695 −3,2156 −2,6473 down −1,5391 down −1,0381 down −1,4827 8,17
33 miR-595 3,3451 −2,4018 −0,8586 up 18,4264 up 53,7046 down −2,9145 0,01
34 miR-642b-3p −3,2695 −3,2156 −1,6936 down −2,9811 down −1,0381 down −2,8717 1,36
35 miR-670 −0,1444 −3,2156 −2,0461 up 3,7365 up 8,4044 down −2,2492 3,14
36 miR-766-3p 0,1875 −2,7920 −1,9239 up 4,3209 up 7,8871 down −1,8253 3,35
37 miR-877-3p −0,9961 −3,2156 −2,7473 up 3,3664 up 4,6572 down −1,3835 0,03
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Validation of dysregulated circulating miRNAs 
by RT-qPCR
The validation of microarray data was performed 
by RT-qPCR on three miRNAs that were differentially 
expressed in the three different cohorts MPM, WEA and 
HS. The results are shown in Tables 2, 3 and 4.
The three miRNAs, miR-197-3p, miR-1281 and 
miR-32-3p, were found up-regulated with both techniques, 
microarray and RT-qPCR, in MPM compared to HS. MiR-
197-3p and miR-1281 were detected in all sera analyzed 
(n= 49). This data allowed us to calculate the difference in 
average of 2-ΔCt by ANOVA, t-test and the FC.
MiR-197-3p 2-ΔCt value found in WEA and HS 
groups was similar, 0.548 and 0.616, respectively, while 
these two 2-ΔCt values are statistically different from 2-ΔCt 
value of 1.139 detected in the MPM group (Figure 4 – 
Panel A).
MiR-197-3p showed a different expression in the 
three cohorts, which is statistically significant by ANOVA, 
with a p= 0.0240. Then, the comparisons between MPM 
vs HS and MPM vs WEA gave p=0.0392 and p= 0.0194 
by t-test, and FC=1.8 and FC= 2.5, respectively. Both 
comparative analyses gave p and FC values statistically 
significant. (Table 3).
MiR-1281 was detected with 2-ΔCt value in MPM 
and WEA of 0.232 and 0.464, respectively. These two 
values differ statistically from 2-ΔCt=0.108 found in the 
HS group (Figure 4 – Panel B). The statistical analysis 
showed that the expression of this miRNA was different in 
the three cohorts by ANOVA with a statistically significant 
p=0.0061. Comparing MPM vs HS, the t-test gave a 
p=0.0121, and FC=2.5, both statistically significant. WEA 
vs HS comparison showed by t-test a p= 0.0.124 and 
the FC=3.5, once again these two values are statistically 
significant (Table 3).
MiR 32-3p was detected by RT-qPCR in only 6/49 
analyzed sera. The low prevalence of 12% of this miRNA 
did not allow us to calculate the fold difference and the 
p-value. Specifically, miR32-3p was detected in 6/20 
(30%) MPM sera, but it was absent in WEA and HS sera. 
(Table 4).
Table 2: Microarray data of differentially expressed miRNAs miR-197-3p miR-1281 and miR-32-3p
Systematic name Comparison Regulation FC ANOVAp
miR-197-3p
MPM vs HS UP 4.4 0.047
MPM vs WEA UP 5.5 0.047
miR-1281
MPM vs HS UP 3.7 0.097
WEA vs HS UP 3.3 0.097
miR-32-3p
MPM vs HS UP 17.6 <0.001
MPM vs WEA UP 61.5 <0.001
Table 3: RT-qPCR data of differentially expressed miRNAs miR-197-3p and miR-1281. The reported ANOVA value 
shows the statistical significance of the three cohorts, and the t-test value indicating the statistical significance in each 
comparison between two groups to underline major differences




MPM vs HS UP 1.8 0.0240* 0.0392*
MPM vs WEA UP 2.5 0.0194*
miR-1281
MPM vs HS UP 2.5 0.0061** 0.0121*
WEA vs HS UP 3.5 0.0.124*
Table 4: RT-qPCR data of differentially expressed miRNAs miR-32-3p
Systematic name Comparison Regulation Pos/tot (% pos) t-test p
miR-32-3p
MPM vs HS UP 6/20 (30%) MPM 0/16 (0%) HS 0.024*
MPM vs WEA UP 6/20 (30%) MPM 0/15 (0%) WEA 0.027*
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DISCUSSION
Circulating miRNA expression in MPM sera has 
been poorly investigated
In our study, high differences in miRNA expression 
profiles in MPM, WEA and HS were identified. (Figure 
1 and 2). Significantly, more miRNAs were expressed 
in the control HS samples than in MPM and WEA sera, 
while the differences in the number of miRNAs detected 
in the three groups are statistically significant. This result 
is in agreement with previous studies on microRNAs 
and human cancers in general, including MPM. Authors 
detected a general down-regulation of miRNAs in tumors 
compared to normal tissues [26]. Moreover, similar results 
were reported in a MPM study. These data showed higher 
miRNA expression profiles in tumors vs. the normal 
tissues [27].
In our investigation miRNA expression profiles 
were analyzed in MPM, WEA and HS sera. It turned out 
that miRNA expression profiles in MPM account for 119 
miRNAs. Interestingly 52 out of 119 miRNA were found 
expressed in MPM only, while they were absent in WEA 
and HS cohorts. In addition, our data showed that in WEA 
42 miRNAs only were detected. However, 40 out of 42 
miRNAs were also detected in the MPM and HS profiles, 
whereas 2 out of 42 miRNAs were present in the HS 
profiles. Considering that the exposure to asbestos fibers 
may induce dysregulation of the immune system [28–
30], one may speculate that the asbestos fibers in WEA 
subjects induces miRNA gene silencing. This may explain 
a reduced number of miRNAs found in this cohort.
In our study, three miRNAs namely miR-197-3p, 
miR-1281 and miR-32-3p were found to be dysregulated. 
This result is strengthened by the identification and 
selection of the stable miR-3665 as the endogenous control 
for quantifying circulating miRNAs in MPM, WEA and 
HS cohorts. MiR-197-3p was resulted up-regulated in 
MPM vs HS with the fold-change of 4.4, whereas it was 
detected up regulated in MPM vs WEA with the fold-
change of 5.5, by microarray analysis. This result is in 
agreement with the RT-qPCR data, which show lower 
ΔCT value in MPM serum groups in comparison with both 
WEA and HS cohorts. Similarly, miR-197-3p was detected 
significantly up-regulated in sera or tissues of a variety of 
human cancer: lung, breast, pancreatic, ovarian, follicular 
thyroid cancer, SCLC, and NSCLC [31–37].
Figure 4: Schematic representation of the Receiver Operating Characteristic (ROC). In Panel A the MiR-197-3p expression 
in MPM, WEA and HS cohorts in the X axis, detected by RT-qPCR, is represented as 2-ΔCt value in the Y axis. The ROC AUC for miR-197-
3p ratio MPM vs HS, p = 0.0328*; 95% confidence interval 0.5398-0.8959, and MPM vs WEA, p = 0.0085**; 95% confidence interval 
0.5981 to 0.9285. Panel B: MiR-1281 expression in sera from MPM patients, WEA and HS, by RT-qPCR. The ROC AUC for miR-1281 
ratio MPM vs HS, p = 0.0112* 95% confidence interval 0.5885-0.9293 and confrontation WEA vs HS, p = 0.0137*; 95% confidence 
interval 0.5963-0.9418. The statistically significant p values are indicate with * and **.
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The strongly up-regulation of miR-197 found in 
MPM sera in comparison with HS and WEA cohorts 
indicates that miR-197 is normally present in sera of 
HS and WEA. Thus, it is possible that asbestos fibers 
penetrated in the lung/mesothelium do not affect the 
release of this miRNA. Subsequently, after the MPM onset 
the release of this miRNA may increase, allowing the 
detection of miR-197 up-regulated. If confirmed by other 
studies this result is particularly significant because miR-
197 could be a new specific biomarker of this neoplasia.
The microRNA.org database indicates the FOXO3 
gene as a predictive target of miR-197. Interestingly, 
FOXO is a key gene promoting the apoptosis process. 
Based on this data, one may speculate that mir-197 
upregulated could lead to the FOXO gene down-regulation, 
which in turn could block the apoptosis of the cancer cells.
MiR-1281 was found up-regulated in MPM vs 
HS with fold-change of 3.7. Comparative analysis 
between WEA with HS sera showed a fold-change 3.3, 
by microarray technique. These results were confirmed 
by RT-qPCR, with a lower ΔCT values in MPM and 
WEA groups in comparison with HS cohort. MiR 32-
3p was investigated in human cancers by three different 
teams. Our data on MPM differ from previous results 
obtained in bladder cancer, where miR 32-3p was found 
down-regulated [38], in adrenocortical tumors it was 
not differentially expressed [39] and in non-131I-avid 
lung metastases of papillary thyroid carcinoma was up-
regulated, compared to in 131I-avid lung metastases [40].
MiR-32-3p resulted up-regulated in MPM vs HS 
group, with a the highest fold-change of 18 in microarray. 
Moreover, comparative analyses MPM vs WEA showed 
this miR up-regulated with a fold-change of 61. The two 
results were confirmed by RT-qPCR: in particular with this 
technique we evidenced the expression of this miRNA only 
in 6 individuals of the MPM group and in none of WEA 
and HS groups. In another study the expression of miR-32-
3p was found up-regulated in HCC and derived cell lines. 
[41]. It has been published that miR-32-3p down-regulates 
phosphatase and tensin homolog (PTEN) through binding 
to 3′-UTR of PTEN mRNA, whereas PTEN was identified 
as a tumor suppressor found mutated in a large number 
of cancers. These data indicate that the expression level 
of miR-32-3p could affect the proliferation, migration, 
and cancer cell invasion. Altogether these results suggest 
that miR-32-3p can be proposed as a potential target for 
cancer treatment [41]. The expression of miR-32-3p 
has been shown to be upregulated in malignancies of 
different histotypes, including kidney [42] and colorectal 
carcinomas (CRC) [43]. Jalava et al demonstrated that has-
miR-32-3p targeted B-cell translocation gene 2 (BTG2), a 
transcriptional cofactor with anti-proliferative properties 
[44]. These data suggest that miR-32-3p has a fundamental 
role as an oncogene. Currently, there are accumulating 
evidences that the aberrant expression of this miRNA is 
linked to the development of different malignancies [43].
It has been proposed that circulating microRNAs 
can be used as new biomarkers. It has been suggested 
that these molecules could act at a distance, moving 
through the circulatory stream. Specific miRNAs can be 
incorporated into biological structures, which may protect 
them from degradation [18]. It was demonstrated that 
exosomes contain microRNA, which can be delivered to 
another cell, and can be functional in this new location 
[45–47]. One may speculate that the up or down regulation 
of circulating miRNAs is not linked to a variation of their 
synthesis within the cells, but they are probably related to 
the release activities into the blood stream.
In HS and WEA sera both miR-197 and miR-32-3 
are expressed at low lever or even absent. In MPM sera an 
enhancement of expression of both these miRNAs is seen. 
Considering that miR-197 down-regulates FOXO3 gene, 
while miR-32-3p downregulates the tumor suppressor 
gene PTEN and the anti-proliferative factor BTG2, these 
events may participate to the MPM onset.
In conclusion, in our experiments a stable miRNA 
was detected and used as endogenous internal control 
(miR-3665), whereas three circulating miRNAs, miR-197-
3p, miR-1281 and miR-32-3p, were found up-regulated in 
MPM compared to HS sera. These three miRNAs could 
function as oncogenes by promoting cell cycle progression 
and cell mobility in MPM as shown before in other human 
cancers. At the same time, these miRNAs probably 
regulate negatively the expression of tumor suppressor 
mRNAs by binding to their 3′UTR. This mechanism 
could generate a positive feedback loop that contributes 
to cancerogenesis.
Up-regulated miR-197-3p, miR-1281 and miR-32-
3p are proposed as new biomarkers for MPM and potential 
targets for innovative cancer treatments. In addition, we 
may speculate that these three dysregulated miRNAs can 
be employed in the group of WEA subjects as markers to 
assess/predict over time the risk of the MPM onset.
MATERIALS AND METHODS
Serum samples
Serum samples were collected from patients affected 
by malignant pleural mesothelioma (MPM) and workers 
both ex-exposed to asbestos fibers (WEA) and healthy 
subjects (HS) at the Clinical Laboratory Analysis of the 
University Hospital of Ferrara, Occupational Medicine 
Unit of the University of Ferrara, and City Hospital of 
Alessandria. Sera were from discarded laboratory analysis 
samples, after routine analyses, before the incineration. 
Anonymously collected sera were coded with indications of 
age, gender and pathology only. Informed written consent 
was obtained from all patients / subjects. The project was 
approved by the Ethics Committee, Ferrara. Italy. Sera, in 
small aliquots, were stored at −80°C until the time of the 
analysis. MicroRNAs analysis by microarray technology 
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was performed on 30 serum samples (n=10 MPM, n=10 
WEA and n=10 HS, with median age of 64 years), whereas 
real time quantitative PCR (RT-qPCR) was extended to 
additional 19 sera, 49 samples total (n=20 MPM, n=15 
WEA and n=14 HS, with median age of 65 years).
RNA extraction
Total RNA, including microRNAs, was extracted 
from 200 μl of serum using miRNeasy Mini Kit (QIAGEN 
cod. 217004) according to manufacturer protocol. The 
final amount of miRNA, extracted from serum, may be 
influenced either miRNA extraction efficiency or RT-
qPCR robustness (i.e. presence of inhibitors). These 
factors can be verified by synthetic non-human miRNAs 
added to the serum sample, employed as controls, before 
the RNA isolation. In order to adjust these parameters, 
synthetic cel-miR-39 miRNA (2.5 μl of 5 nM) was added 
to the serum sample (200 ul), soon after adding the Qiazol 
Reagent (1 ml). RNA was eluted in 30 μl RNAse-free 
water.
MicroRNA microarray
MicroRNA expression profile was analyzed in 30 
samples, n=10 MPM, n=10 WEA and n=10 HS, using the 
Agilent miRNA microarray (G4870A) technology. This 
array is capable to assess the expression of 1,201 human 
miRNAs. A constant volume of 8 μl RNA was employed 
for the hybridization procedure. Experiments were 
performed as previously described [14, 48]. Microarray 
raw data were analyzed using GeneSpring GX 13 software 
(Agilent Technologies). A quantile normalization was 
applied before statistical analyses. A signal was detectable 
(i.e. above background) in at least one sample for 197 
miRNA probes.
Microarray data analysis
MicroRNAs, differentially expressed in the three 
groups (MPM, WEA and HS) were identified having a 1.5 
fold differential expression and a false discovery rate < 
10% in ANOVA statistical analysis (GeneSpring software).
Reverse transcription
Reverse transcription reactions (10 μL) were 
performed using miRCURY LNA Universal RT 
microRNA PCR (EXIQON: cod EX203301). Two μL of 
total RNA was reverse transcribed after adding 0.5 μL of 
Synthetic RNA spike-in UniSp6, as an exogenous control. 
Reactions were carried out on the PTC-100 thermal cycler 
(MJ Research) using the following conditions: 42°C for 
60 min, 95°C for 5 min, and then hold at 4°C. RT products 
were stored at −20°C until the time of the real-time PCR 
analysis. Cel-miR-39 assay was performed to monitor RT 
reaction efficacy.
RT-qPCR analysis of endogenous miRNAs
Reverse Transcription Quantitative PCR (RT-qPCR) 
analysis was performed to validate three differentially 
expressed miRNAs from microarray analysis. These 
miRNAs were miR-1281, miR-197-3p, and miR 32-3p. 
In addition, three reference miRNAs, miR-1234-3p, miR-
3656 and miR-3665, which showed stable expression, 
were valided. This approach was employed with the 
aim to select stable endogenous controls to quantify the 
circulating miRNAs. RT-qPCR reactions were performed 
using a ExiLENT SYBR® Green master mix (EXIQON) 
according to the manufacturer’s instructions. Briefly, 1:40 
diluted cDNA template was added to PCR primer mix and 
PCR Master mix, in 10 μL. Samples were run in triplicate 
(CFX96 Touch Real-Time PCR Detection System, 
Applied Biosystems) with denaturation at 95°C 10 min, 
followed by 40 cycles at 95°C 10 s, 60°C 1 min. A final 
melting curve analysis, from 60°C to 95°C, was carried 
out to verify the presence of a single amplified product.
Determination of reference genes
For each candidate reference miRNA, the 
expression variability was assessed by calculating the 
overall coefficient of variability (CV). Each candidate 
endogenous control miRNA was tested in triplicate 
in RT-qPCR and the results expressed as mean Ct. To 
confirm the invariability we used also two statistical 
methods ANOVA test and NormFinder (http://moma.dk/
normfinder-software); this software evaluted the stability 
and rank of each candidate house-keeping miRNA. The 
algorithm of NormFinder uses a mathematical model and a 
solid statistical framework to calculate the gene expression 
stability. NormFinder estimates the overall expression 
validation of the candidate normalizer genes, as well as 
the intra-group and the inter-group variations.
Validation of circulating miRNAs expression
The level of three miRNAs, miR-1281, miR-197-
3p and miR 32-3p, which resulted differentially expressed 
according to microarray analysis, was measured by RT-
qPCR. MiRNA expression level was measured using the 
ΔCt method, where the Ct threshold cycle is the fractional 
cycle number when the fluorescence of each sample passes 
a fixed threshold. Relative quantification of each miRNAs 
was performed using as a references gene (HKmiR) a 
chosen stable endogenous control miRNA, which shows 
stably expression in all sera. The results were expressed 
as ΔCT (CtmiR-CtHKmiR) for each subject and as mean ± 
S.D. of ΔCT for each group. High miRNA ΔCT value 
corresponded to low miRNA expression. The fold changes 
in relative miRNA expression were calculated using the 
equation 2-Δ(ΔCt), where
ΔΔCt = (CtmiR-CtHKmiR)MMP - (CtmiR-CtHKmiR)HS.
Oncotarget82709www.impactjournals.com/oncotarget
MiRNA species that were not detected in any of 
samples or with a CT value >39 were excluded from 
the comparison. MiRNA species with at least a 1.5-
fold expression change among groups were considered 
differentially expressed.
Receiver Operating Characteristic (ROC) analysis 
was used to quantify the accuracy of a RT-qPCR result 
in discriminating comparative data of MPM vs HS, MPM 
vs WEA and WEA vs HS. The resulting ROC curve was 
generated by plotting true positive rate against false 
positive rate, at different threshold settings. The area under 
the curve (AUC) represents the probability that a random 
MPM/WEA is ranked as higher than a randomly chosen 
WEA/HS, the control. The highest AUC value = 1 means 
that the test perfectly discriminates MPM/WEA from the 
control, either WEA or HS.
Statistical analysis
The statistical analysis was performed using 
Prism 4.0 statistical software (GraphPad software, La 
Jolla, CA, USA). Chi-square was employed to study 
the differences in the total number of miRNAs detected 
in the three groups. ANOVA test was employed to study 
the differences in mean ΔCT of 2 dysregulated miRNAs 
(miR-1281 and miR-197-3p) and three stably expressed 
miRNAs, miR-1234-3p, miR-3656 and miR-3665, in the 
three cohorts, MPM, WEA and HS. ANOVA test and t-test 
were employed to confirm the fold-change obtained from 
ΔΔCt method.
Data for the dysregulated miR 32-3p are presented 
as a percentage of positive MPM analyzed sera. The 95% 
Confidence Intervals (CI) of the percentage of positive 
samples are also reported. Differences among proportions 
were calculated by Chi-square test for independence in the 
contingency tables. P value <0.05 was considered to be 
statistically significant.
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